Uterine Myomas
9
0
0
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
67%
6 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Predictive Factors for Complete Myoma Resection During Hysteroscopic Myomectomy
Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery
Vasopressin Versus Epinephrine in Myomectomy
Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy
Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids
PGL4001 Versus GnRH-agonist in Uterine Myomas
PGL4001 Versus Placebo in Uterine Myomas
Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators
Single-port Access Laparoscopic-assisted Vaginal Hysterectomy